Published in Med Decis Making on November 18, 2013
Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample: A Fast, Nonparametric Regression-Based Method. Med Decis Making (2015) 1.20
Value of Information: A Tool to Improve Research Prioritization and Reduce Waste. PLoS Med (2015) 0.78
Estimating the expected value of partial perfect information in health economic evaluations using integrated nested Laplace approximation. Stat Med (2016) 0.78
Value of Information Analysis Applied to the Economic Evaluation of Interventions Aimed at Reducing Juvenile Delinquency: An Illustration. PLoS One (2015) 0.78
The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Serv Res (2017) 0.78
Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. Pharmacoeconomics (2016) 0.76
Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study. BMJ Open (2017) 0.75
Community IntraVenous Antibiotic Study (CIVAS): protocol for an evaluation of patient preferences for and cost-effectiveness of community intravenous antibiotic services. BMJ Open (2015) 0.75
The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care. BMC Cardiovasc Disord (2017) 0.75
A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models. Pharmacoeconomics (2017) 0.75
Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer. Pharmacoeconomics (2017) 0.75
The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. Pharmacoeconomics (2017) 0.75
An economic approach to clinical trial design and research priority-setting. Health Econ (1997) 2.54
Expected value of sample information calculations in medical decision modeling. Med Decis Making (2004) 2.04
Decision analysis: introductory lectures on choices under uncertainty. 1968. MD Comput (1993) 2.02
Sensitivity analysis and the expected value of perfect information. Med Decis Making (1998) 1.56
Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. Health Technol Assess (2004) 1.17
Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. Health Econ (2006) 1.14
Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information. Value Health (2013) 1.05
Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. Med Decis Making (2007) 1.04
An efficient method for computing single-parameter partial expected value of perfect information. Med Decis Making (2012) 0.92
Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making (2004) 0.92
Simulation sample sizes for Monte Carlo partial EVPI calculations. J Health Econ (2010) 0.89
Estimating expected value of sample information for incomplete data models using Bayesian approximation. Med Decis Making (2011) 0.86
Gaussian process metamodeling in Bayesian value of information analysis: a case of the complex health economic model for breast cancer screening. Value Health (2008) 0.81
Policy options for alcohol price regulation: the importance of modelling population heterogeneity. Addiction (2009) 4.61
Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model. Lancet (2010) 3.82
Alcohol tax pass-through across the product and price range: do retailers treat cheap alcohol differently? Addiction (2014) 1.62
Adjusting for unrecorded consumption in survey and per capita sales data: quantification of impact on gender- and age-specific alcohol-attributable fractions for oral and pharyngeal cancers in Great Britain. Alcohol Alcohol (2013) 1.59
A critique and impact analysis of decision modeling assumptions. Med Decis Making (2007) 1.44
The temporal relationship between per capita alcohol consumption and harm: a systematic review of time lag specifications in aggregate time series analyses. Drug Alcohol Depend (2011) 1.34
Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum (2008) 1.28
Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics (2005) 1.27
Should patients have a greater role in valuing health states? Appl Health Econ Health Policy (2005) 1.27
Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Making (2012) 1.22
Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England. Alcohol Alcohol (2012) 1.15
Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. Value Health (2012) 1.05
The impact of spatial and temporal availability of alcohol on its consumption and related harms: a critical review in the context of UK licensing policies. Drug Alcohol Rev (2014) 1.02
A theory-based online health behavior intervention for new university students: study protocol. BMC Public Health (2013) 0.95
An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists. Drugs (2005) 0.93
An efficient method for computing single-parameter partial expected value of perfect information. Med Decis Making (2012) 0.92
Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin (2005) 0.92
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharm Stat (2009) 0.91
Simulation sample sizes for Monte Carlo partial EVPI calculations. J Health Econ (2010) 0.89
Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value Health (2008) 0.88
A theory-based online health behaviour intervention for new university students (U@Uni): results from a randomised controlled trial. BMC Public Health (2014) 0.87
Estimating expected value of sample information for incomplete data models using Bayesian approximation. Med Decis Making (2011) 0.86
Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making (2004) 0.85
Decision modeling to inform decision making: seeing the wood for the trees. Med Decis Making (2010) 0.84
Cost-effectiveness of a programme of screening and brief interventions for alcohol in primary care in Italy. BMC Fam Pract (2014) 0.84
Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. Value Health (2012) 0.80
Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. BMJ Open (2013) 0.80
Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community. BMC Health Serv Res (2013) 0.80
Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. Pharm Stat (2009) 0.79
Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model. Value Health (2013) 0.79
Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule. Vaccine (2002) 0.79
A prognostic model for functional outcome in early rheumatoid arthritis. J Rheumatol (2006) 0.78
The Sheffield rheumatoid arthritis health economic model. Rheumatology (Oxford) (2011) 0.78
Reporting the characteristics of the policy context for population-level alcohol interventions: a proposed 'Transparent Reporting of Alcohol Intervention ContExts' (TRAICE) checklist. Drug Alcohol Rev (2014) 0.77
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry (2010) 0.77
Evaluation of the impact of a technology appraisal process in England: the South and West Development and Evaluation Committee. J Health Serv Res Policy (2003) 0.77
The cost-effectiveness of a theory-based online health behaviour intervention for new university students: an economic evaluation. BMC Public Health (2014) 0.77
Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom. Int J Technol Assess Health Care (2009) 0.76
Assurance calculations for planning clinical trials with time-to-event outcomes. Stat Med (2013) 0.75
The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture. Med Decis Making (2009) 0.75
The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies. Eur J Health Econ (2012) 0.75
Bayesian inference for comorbid disease risks using marginal disease risks and correlation information from a separate source. Med Decis Making (2011) 0.75
A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res (2005) 0.75
A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. Int J Cardiol (2008) 0.75